Biomarkers in stable coronary artery disease

Cian P. McCarthy; John W. McEvoy; James L. Januzzi

doi:10.1016/j.ahj.2017.10.016

Biomarkers in stable coronary artery disease

Cian P. McCarthy
, John W. McEvoy
, James L. Januzzi

Massachusetts General Hospital
The Johns Hopkins University School of Medicine
Harvard Clinical Research Institute

Research output: Contribution to a Journal (Peer & Non Peer) › Review article › peer-review

41 Citations (Scopus)

Abstract

Coronary artery disease (CAD) remains a significant cause of morbidity and mortality around the world. Patients with stable CAD can have an unpredictable clinical trajectory; thus, additional tools to prognosticate risk in this cohort are warranted. In recent years, a wide range of biomarkers has been recognized for their diagnostic capabilities in patients with stable CAD, identifying those with obstructive disease who may require more intensive preventive therapies or even consideration of percutaneous coronary intervention in some circumstances. In addition, a multiple-biomarker approach may identify stable CAD patients at highest risk for future major adverse cardiac events. Thus, randomized controlled trials to assess biomarker-guided preventive therapy in this cohort appear warranted.

Original language	English
Pages (from-to)	82-96
Number of pages	15
Journal	American Heart Journal
Volume	196
DOIs	https://doi.org/10.1016/j.ahj.2017.10.016
Publication status	Published - Feb 2018
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.ahj.2017.10.016

Cite this

@article{f474e882c3c4498a99d72defe616c2dc,

title = "Biomarkers in stable coronary artery disease",

abstract = "Coronary artery disease (CAD) remains a significant cause of morbidity and mortality around the world. Patients with stable CAD can have an unpredictable clinical trajectory; thus, additional tools to prognosticate risk in this cohort are warranted. In recent years, a wide range of biomarkers has been recognized for their diagnostic capabilities in patients with stable CAD, identifying those with obstructive disease who may require more intensive preventive therapies or even consideration of percutaneous coronary intervention in some circumstances. In addition, a multiple-biomarker approach may identify stable CAD patients at highest risk for future major adverse cardiac events. Thus, randomized controlled trials to assess biomarker-guided preventive therapy in this cohort appear warranted.",

author = "McCarthy, \{Cian P.\} and McEvoy, \{John W.\} and Januzzi, \{James L.\}",

note = "Publisher Copyright: {\textcopyright} 2017 Elsevier Inc.",

year = "2018",

month = feb,

doi = "10.1016/j.ahj.2017.10.016",

language = "English",

volume = "196",

pages = "82--96",

journal = "American Heart Journal",

issn = "0002-8703",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Biomarkers in stable coronary artery disease

AU - McCarthy, Cian P.

AU - McEvoy, John W.

AU - Januzzi, James L.

PY - 2018/2

Y1 - 2018/2

N2 - Coronary artery disease (CAD) remains a significant cause of morbidity and mortality around the world. Patients with stable CAD can have an unpredictable clinical trajectory; thus, additional tools to prognosticate risk in this cohort are warranted. In recent years, a wide range of biomarkers has been recognized for their diagnostic capabilities in patients with stable CAD, identifying those with obstructive disease who may require more intensive preventive therapies or even consideration of percutaneous coronary intervention in some circumstances. In addition, a multiple-biomarker approach may identify stable CAD patients at highest risk for future major adverse cardiac events. Thus, randomized controlled trials to assess biomarker-guided preventive therapy in this cohort appear warranted.

AB - Coronary artery disease (CAD) remains a significant cause of morbidity and mortality around the world. Patients with stable CAD can have an unpredictable clinical trajectory; thus, additional tools to prognosticate risk in this cohort are warranted. In recent years, a wide range of biomarkers has been recognized for their diagnostic capabilities in patients with stable CAD, identifying those with obstructive disease who may require more intensive preventive therapies or even consideration of percutaneous coronary intervention in some circumstances. In addition, a multiple-biomarker approach may identify stable CAD patients at highest risk for future major adverse cardiac events. Thus, randomized controlled trials to assess biomarker-guided preventive therapy in this cohort appear warranted.

UR - https://www.scopus.com/pages/publications/85035751004

U2 - 10.1016/j.ahj.2017.10.016

DO - 10.1016/j.ahj.2017.10.016

M3 - Review article

C2 - 29421018

AN - SCOPUS:85035751004

SN - 0002-8703

VL - 196

SP - 82

EP - 96

JO - American Heart Journal

JF - American Heart Journal

ER -

Biomarkers in stable coronary artery disease

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this